OneSource Specialty Pharma Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹290.34 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 22.73 per cent from ₹375.76 crore. This corresponds to a year-on-year *(YoY) decline of 26.04 per cent.
Operating Profit
Operating Profit stands at ₹42.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 15.84 per cent from ₹37.00 crore. This corresponds to a year-on-year *(YoY) decline of 18.42 per cent.
PBDT
PBDT stands at ₹65.33 crore, reflecting a quarter-on-quarter *(QoQ) increase of 0.37 per cent from ₹65.09 crore. This corresponds to a year-on-year *(YoY) decline of 8.14 per cent.
Profit Before Tax
Profit Before Tax stands at ₹-93.01 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1,717.57 per cent from ₹5.75 crore. This corresponds to a year-on-year *(YoY) growth of 39.86 per cent.
Net Profit
Net Profit stands at ₹-81.61 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 877.98 per cent from ₹10.49 crore. This represents a 357.69 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
OneSource Specialty Pharma Ltd News
OneSource Specialty Pharma Ltd Earnings
- YOY
- QOQ
OneSource Specialty Pharma Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
OneSource Specialty Pharma Ltd Research Reports
OneSource Specialty Pharma Ltd Financial Reports
OneSource Specialty Pharma Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| OneSource Speci. | 5.19% | 5.17% | -26.78% | -27.21% | -31.44% | -7.74% |
| Natco Pharma | 0.18% | 3.92% | 4.60% | 8.63% | 1.14% | 5.93% |
| Alembic Pharma | 1.15% | -2.78% | 1.12% | -14.73% | -19.98% | -3.90% |
| Jubilant Pharmo | 1.79% | -3.40% | -8.72% | -20.21% | -14.13% | -9.38% |
| Granules India | 0.09% | -2.54% | -1.73% | 0.39% | 22.22% | 8.91% |
| Caplin Point Lab | 0.72% | -0.83% | -4.44% | -9.50% | -19.52% | -10.25% |
| Rubicon Research | 0.65% | 1.76% | 19.59% | 9.56% | 26.58% | 26.58% |
Company Info
Company Information
Chairman & Non Executive Dir. : Arun Kumar
Managing Director & CEO : Neeraj Sharma
Independent Non Exe. Director : Debarati Sen
Independent Non Exe. Director : Claudio Albrecht
Independent Non Exe. Director : Rashmi Harshadrai Barbhaiya
Independent Non Exe. Director : Vijay Paul Karwal
Independent Non Exe. Director : Colin Michael Bond
Non Executive Director : Bharat Shah
Company Sec. & Compli. Officer : Trisha A